Lilly(Eli) & Co

NYSE:LLY   3:59:58 PM EDT
244.90
+1.15 (+0.47%)
Products

FDA Expands Lilly's ERBITUX (Cetuximab) Label With Combination Of Braftovi (Encorafenib)

Published: 09/28/2021 22:20 GMT
Lilly(Eli) & Co (LLY) - FDA Expands Lilly's Erbitux® (cetuximab) Label With Combination of Braftovi® (encorafenib) for the Treatment of Braf V600e Mutation-positive Metastatic Colorectal Cancer (crc) After Prior Therapy.
Eli Lilly - Erbitux Has Now Received Seven FDA Approvals to Treat Certain Types of Crc and Squamous Cell Carcinoma of Head and Neck.